
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.614 | -17.1988795518 | 3.57 | 3.97 | 2.76 | 930835 | 3.32299912 | CS |
4 | 0.806 | 37.488372093 | 2.15 | 3.97 | 2.045 | 912844 | 3.26652928 | CS |
12 | 1.476 | 99.7297297297 | 1.48 | 3.97 | 1.05 | 588025 | 2.4196915 | CS |
26 | 0.886 | 42.8019323671 | 2.07 | 3.97 | 1.05 | 539785 | 2.103138 | CS |
52 | 0.296 | 11.1278195489 | 2.66 | 4.13 | 1.05 | 616019 | 2.56487791 | CS |
156 | -3.554 | -54.5929339478 | 6.51 | 10.88 | 0.359908 | 576810 | 3.01472935 | CS |
260 | -38.724 | -92.9078694818 | 41.68 | 56.5899 | 0.359908 | 438870 | 7.8964839 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.